Further, application of the neurotoxin that mimics Parkinson’s disease, 1-methyl-4-phenyl-1,2,3,6-tetrahyrdro-pyridine (MPTP), led to increased activity of Cav1.3, and decreased expression of TRPC1 and inhibited thapsigargin mediated STIM1-Cav1.3 interactions (Sun et al., 2017). Here, CACNA1D is linked to Parkinson disease.